2022

dbb-wp
3 years

Duopharma Biotech Strengthens Good Governance with New Integrity Programme and Industry Recognition

Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.

dbb-wp
3 years

Duopharma Biotech Records Milestone with First Halal-Certified Cancer Treatment

Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.

dbb-wp
3 years

Duopharma Biotech Integrity and Anti-Corruption Series

Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.

dbb-wp
3 years

Duopharma Biotech Sponsors the UNGCMYB GO ESG ASEAN 2022 Summit

Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.

dbb-wp
3 years

Duopharma Biotech Records 10.33% Rise In Cumulative Revenue in 3Q 2022

Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.

dbb-wp
3 years

Duopharma Biotech to Commercialise SCM Lifescience’s Stem Cell Based Hair Care Products in Malaysia and Region Under its Consumer Healthcare Business.

Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.

dbb-wp
3 years

Duopharma Biotech Delivers Better Earnings in 2Q 2022

Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.

Duopharma Media
3 years

Duopharma Biotech And The Live Green Co To Develop Plant-Only Wellness Foods and Plant Based Pharmaceuticals in Malaysia

KUALA LUMPUR, 14 JULY 2022 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) and US-based foodtech company The Live Green Co. signed a Collaboration Agreement today to explore the use of plant ingredients and technology to replace animal, synthetic and ultra-processed ingredients, to meet consumer demand for more sustainable wellness foods and pharmaceuticals.

Duopharma Media
3 years

Duopharma Biotech Maintains High Productivity Amidst Focus on Innovation

● Duopharma Biotech Berhad’s 21st AGM reaffirms the Group’s commitment to maintaining its leading position as an innovative pharmaceutical company in Malaysia and a global leader in the halal sector
● Intensified focus on ESG has made the Group a preferred employer, trusted partner, attractive investment and an increasingly strong brand

Duopharma Media
3 years

Duopharma Biotech Spurs Efforts to Capture Global Halal Pharma Market via Halal Pharmaceuticals Symposium

Kuala Lumpur, June 15, 2022 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company“) hosted the Third (3rd) Halal Pharmaceuticals Symposium 2022 today, as part of The Company’s continuing quest to spearhead efforts to capture the global halal pharmaceuticals market by facilitating the sharing of best practices, achievements and international collaborations to resolve challenges, advance global standards and jointly shape the industry.